The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

J. Yu, Q. Cao, J. Yu, L. Wu, A. Dallol, J. Li, G. Chen, C. Grasso, X. Cao, R. J. Lonigro, S. Varambally, R. Mehra, N. Palanisamy, J. Y. Wu, F. Latif, A. M. Chinnaiyan

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer.

Original languageEnglish (US)
Pages (from-to)5370-5380
Number of pages11
JournalOncogene
Volume29
Issue number39
DOIs
StatePublished - Sep 30 2010

    Fingerprint

Keywords

  • DNA hypermethylation
  • EZH2
  • Epigenetic silencing
  • Polycomb group proteins
  • Prostate cancer
  • SLIT2

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Yu, J., Cao, Q., Yu, J., Wu, L., Dallol, A., Li, J., Chen, G., Grasso, C., Cao, X., Lonigro, R. J., Varambally, S., Mehra, R., Palanisamy, N., Wu, J. Y., Latif, F., & Chinnaiyan, A. M. (2010). The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene, 29(39), 5370-5380. https://doi.org/10.1038/onc.2010.269